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1684-1182/Copyright ª 2015, TaiwanAbstract Background/Purpose: Human parvovirus B-19 (PB-19) is a cause of hemolysis, red
blood cell aplasia, and severe conditions in patients with sickle cell anemia, but the molecular
mechanisms of the infection are still insufficiently understood. This study aimed to detect PB-
19 DNA together with its antibodies in the sera of Egyptian children with sickle cell disease and
to assess the contribution of this infection, which causes transient cessation of erythropoiesis,
in precipitating severe anemia in some cases.
Methods: One hundred children with sickle cell disease seeking medical advice in the
pediatric-hematology clinic were recruited. Sera of the patients were compared with those
of 60 healthy children regarding the presence of PB-19 immunoglobulin (Ig)G and IgM as well
as detection of its DNA by nested-polymerase chain reaction technique.
Results: There were statistically significant differences in the prevalence of PB-19 IgM, IgG,
and DNA among patients when compared with controls (p < 0.001, p Z 0.001, and
p < 0.001 respectively). Acute PB-19 infection detected by positive IgM and DNA was found
in 30% of the patients, while chronic PB-19 infection detected by positive IgG and DNA was de-
tected in 24% of the patients. Anemia was worse in children with acute PB-19 infection than in
those with chronic infection, while anemia was mild in children with old infection.
Conclusion: PB-19 infection is detected at high rates among Egyptian children with sickle cell
disease and it may result in severe anemia. So, PB-19 must be suspected and screened for in
such group of patients.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.of Clinical and Chemical Pathology, Faculty of Medicine, El-Kasr El-Aini Hospital, Cairo University, El-
yahoo.com (M.M. Makhlouf).
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+ MODELIntroductionHuman parvovirus B-19 (PB-19), a member of parvoviridae
family, is a common infectious pathogen in humans pri-
marily found in children.1 The PB-19 virus has a specific
tropism for erythroid progenitor cells and thus can cause a
temporary infection of the bone marrow eventually leading
to impaired erythropoiesis for 7e10 days and transient ar-
rest for 3e7 days.2 The effect of this on hemoglobin level
varies by individual. In healthy children, a mild decrease in
hemoglobin levels might occur,3 whereas a greater
decrease has been described in children with iron defi-
ciency and malaria.4
In patients with sickle cell disease and other hemolytic
anemia, erythroid progenitor cell formation is increased to
compensate for red blood cell lysis, but a precipitous
decrease in hemoglobin level can be induced through the
combination of a high rate of red blood cell destruction and
complete cessation of red blood cell production inducing
erythropoiesis suppression caused by PB-19, which is often
referred to as transient aplastic crisis.5 These patients are
at risk of severe clinical illness and become highly viremic.
Close monitoring of such high risk groups for this viral
infection is, therefore, of great importance for epidemio-
logic surveillance and disease prevention.6
Traditionally, the diagnosis of acute PB-19 disease has
been based solely upon the detection of PB-19 immuno-
globulin (Ig)M which appears only on days 8e10 post-
infection.3 Virus-induced bone marrow suppression begins
to recover on day 16 and the PB-19 IgM usually becomes
undetectable after 2e4 months depending on the initial
level of response,7 although persistence for up to 9 months
has been reported.8 After PB-19 virus infection, IgG per-
sists, which is generally useful for diagnosis of chronic or
old infection.9
Major advances in diagnosis of PB-19 infection have
taken place including standardization of serological and
DNA based detection methodology.10 As there is no reliable
immunological method for antigen detection, polymerase
chain reaction (PCR) is needed for detecting viremia.11
Combined use of PCR and enzyme-linked immunosorbent
assay (ELISA) are optimal for diagnosis of PB-19
infection.12
The aim of this study was to detect PB-19 DNA together
with its antibodies in the sera of Egyptian children with
Sickle cell disease and to assess the contribution of this
infection, which causes transient cessation of erythropoi-
esis, in precipitating severe anemia in some cases.
Methods
This was a prospective, observational study performed in
the Pediatric-Haematology Department of Elmounira Chil-
dren Hospital, Faculty of Medicine, Cairo University, Cairo,
Egypt. It was conducted on 100 Egyptian children with
sickle cell disease who were seeking medical advice in the
pediatric-hematology clinic; 64 of them were diagnosed as
sickle cell anemia (homozygous SS) and 36 as sickle cell
trait (heterozygous AS). Thirty patients were presented
with acute aplasic crisis (a precipitous drop in hemoglobin
level occurs in the absence of adequate reticulocytosis).5Please cite this article in press as: Makhlouf MM, et al., Molecular an
children with sickle cell disease, Journal of Microbiology, Im
j.jmii.2015.10.016The mean age was 7.8  1.7 years, 53% of them were
males and 47% were females. Sixty age- and sex-matched
normal healthy children living in the same area who came
for routine checkup in the pediatric clinic were also
included as a control group. Written informed consent was
obtained from the parents of all the participants as well as
Ethical Committee approval.
All children were subjected to complete history taking
and full clinical examination. Routine laboratory in-
vestigations were carried out including complete blood
picture, reticulocyte count, sickling test, and hemoglobin
electrophoresis. Virological study for PB-19 included
determination of specific IgG and IgM by ELISA together
with viral DNA by nested-PCR were performed.
Detection of PB-19 IgG and IgM by ELISA
Serum samples were obtained for detection of PB-19 spe-
cific IgG and IgM antibodies by ELISA using a commercial
assay (Parvoscan-B19; Biotrin International, Dublin,
Ireland), according to the manufacturer’s instructions. This
assay detects antibodies directed against viral protein VP2.
The IgM enzyme immunoassay (EIA) kit has a reported
sensitivity of 86% and specificity of 95% (Parvovirus B-19 IgM
Biotrin International) and the IgG EIA has a reported
sensitivity and specificity of 100% (Parvovirus B-19 IgG Bio-
trin International). Positive (reactive) and negative
(nonreactive) samples were calculated according to the
manufacturer’s recommendations.
Detection of PB-19 DNA by nested-PCR
Serum samples were further subjected to DNA extraction
using the QIAamp DNA blood kit (Qiagen, Hilden, Germany)
as described by the manufacturer. The extracted DNA was
subsequently used as a template for the detection of PB-19
DNA by nested-PCR using two primer pairs that targeted
the minor (VP1) and major (VP2) capsid protein genes ac-
cording to Regaya et al.8 The outer primers were: sense, 50-
CAAAAGCATGTGGAGTGAGG-30; antisense, 50-CTACTAA-
CATGCATAGGCGC-30. The inner primers were; sense, 50-
CCCAGAGCACCATTATAAGG-30; antisense, 50-GTGCTGTCAG-
TAACCTGTAC-30. Each PCR assay was a 50 mL reaction
mixture containing 5 mL of extracted DNA sample, 50mM
KCl, 10mM Tris-HCl (pH 8.3), 1.5mM MgCl2, 200mM of each
deoxyribonucleoside triphosphate, 1.25 U of Taq DNA po-
lymerase (Promega, Madison, WI, USA), 0.5mM of each
outer or inner primers (Biomers, Ulm, Germany), and
DNAse free water. Positive control DNA (cloned PB-19 virus)
to establish the specificity of the reaction. Internal control
for b-globin gene was included for each sample to exclude
false negative results. Amplification reactions were per-
formed in a thermocycler program, consisting of one cycle
of denaturation at 94C for 5 minutes, 30 cycles denatur-
ation at 94C for 1 minute, annealing at 55C with outer
primers or 57C with inner primers for 2 minutes and
extension at 72C for 3 minutes and a final extension step
at 72C for 5 minutes. Both primary and secondary PCR
products as well as b-globin were separately electro-
phoresed on 2% agarose gel prestained with ethidium bro-
mide and visualized on a UV transilluminator (wave lengthd serological assessment of parvovirus B-19 infection in Egyptian
munology and Infection (2015), http://dx.doi.org/10.1016/
Table 1 Comparison between the children with sickle cell
disease and the control group.
Items Study group
(n Z 100)
Control group
(n Z 60)
p
Age (y) 7.81  1.74 7.14  1.85 0.115
Sex
Male 50 (50) 26 (43.3)
0.563
Female 50 (50) 34 (56.7)
Hemoglobin (g%) 8.38  1.39 12.45  1.98 <0.001
RBCs ( 106/mL) 4.15  0.91 5.16  1.08 <0.001
Hematocrit (%) 25.62  3.97 34.31  2.65 <0.001
IgM positivity 30 (30) 0 (0%) <0.001
IgG positivity 44 (44%) 6 (10%) 0.001
Parvovirus B-19 DNA
detection by PCR
54 (54%) 2 (3.3%) <0.001
Acute infection
(IgM & PCRþve)
30 (30) 0 (0) <0.001
Chronic infection
(IgG & PCRþve)
24 (24) 2 (3.3) 0.015
Old infection
(Anti-parvovirus
B-19 IgG þve)
20 (20) 4 (6.7) 0.106
Data are presented as n (%) or mean  standard deviation.
Ig Z immunoglobulin; PCR Z polymerase chain reaction;
RBCs Z red blood cells.
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+ MODEL312 nm) obtaining bands of sizes 398 bp, 288 bp, and 208 bp
respectively after extrapolation for mobility with 100 bp
ladder DNA markers (Invitrogen, Carlsbad, CA, USA) as
shown in Fig. 1.
Statistical analysis
Data were collected and tabulated using Excel version 7
(Microsoft Corporation, New York, USA) and analyzed using
SPSS for Windows version 11 (SPSS Inc., Chicago, IL, USA).
All data were described in terms of mean and standard
deviation. Paired and independent sample Student t test
was used after assessing the normal distribution of values to
compare between the two groups. The c2 test, or the
Fisher’s exact test (2-tailed) if appropriate, was applied for
the categorical variables, and KruskaleWallis one-way
analysis of variance (ANOVA) for continuous variables. A p
value < 0.05 was considered statistically significant.
Results
The results of PB-19 IgM and IgG antibodies and its DNA for
patients and controls are summarized in Table 1. There
were statistically significant differences in the prevalence
of PB-19 IgM, IgG, and DNA among the patients when
compared with the controls (p < 0.001, p Z 0.001, and
p < 0.001 respectively). Acute parvovirus infection was
detected in 30% of the patients presented with sickle cell
disease, while not detected (0%) in the control groupFigure 1. Agarose gel electrophoresis pattern of parvovirus
B-19 (PB-19) DNA amplicons in sickle cell disease patients. (A)
b-globin DNA bands serves as an internal control. (B) PB-19 DNA
bands obtained in the first round of polymerase chain reaction.
(C) PB-19 DNA bands obtained in the second round of poly-
merase chain reaction. Lanes 1e6 Z amplicons of sera from
Patients 1e6, respectively; M Z molecular weight marker
(100e1500 bp ladder); P Z positive control.
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j.jmii.2015.10.016(p < 0.001), whereas chronic infection was detected in only
24% of the patients versus 3.3% of the controls (pZ 0.015).
Moreover, there was no difference between the two groups
regarding the presence of old infection (p Z 0.106).
Table 2 shows comparison between the study population
with sickle cell disease according to their clinical presen-
tation whether they came with aplastic crisis (30 patients)
or without crisis (70 patients). Acute parvovirus infection
was detected in 86.6% of the patients presented with
aplastic crisis, while only in 5.7% of those without crisis
(p < 0.001), whereas chronic and old infections were
detected in only 6.7% and 6.7% of the patients with crisis
versus 31.4% and 25.7% of those without crisis respectively.
These differences were not statistically significant
(p Z 0.062 and p Z 0.123, respectively).
When the patients with sickle cell disease were classi-
fied according to PB-19 infection into acute infection (IgM
positive and DNA detection by PCR), chronic infection (IgG
positive and DNA detection by PCR), old infection (IgG
positive only), and no PB-19 infection (IgM, IgG negative
and no DNA detection by PCR), as shown in Table 3, sta-
tistically significant differences between the three groups
regarding hemoglobin level, red blood cells count, and
hematocrit values were found (p Z 0.006, p Z 0.016, and
p Z 0.003 respectively). Anemia was worse in children
with acute PB-19 infection than in those with chronic
infection, while anemia was mild in children with old PB-
19 infection.
Discussion
Parvovirus B-19 infection in humans is distributed world-
wide. Certain populations are vulnerable to complicationsd serological assessment of parvovirus B-19 infection in Egyptian
munology and Infection (2015), http://dx.doi.org/10.1016/
Table 2 Comparison between patients with sickle cell disease with and without acute aplastic crisis.
Items Sickle cell patients with acute
aplastic crisis (n Z 30)
Sickle cell patients without acute
aplastic crisis (n Z 70)
p
Hemoglobin (g%) 6.41  0.36 8.91  1.34 <0.001
RBCs ( 106/mL) 3.81  0.35 4.13  0.61 0.021
Hematocrit (%) 20.07  1.09 27.88  1.76 <0.001
Acute infection
(IgM & PCRþve)
26 (86.6) 4 (5.7) <0.001
Chronic infection
(IgG & PCRþve)
2 (6.7) 22 (31.4) 0.062
Old infection
(Anti-parvovirus B-19 IgG þve)
2 (6.7) 18 (25.7) 0.123
Data are presented as n (%) or mean  standard deviation.
Ig Z immunoglobulin.
Table 3 Comparison between patients with acute, chronic, old and no parvovirus B-19 infection.
Items Acute infection
(n Z 30)
Chronic infection
(n Z 24)
Old infection
(n Z 20)
No infection
(n Z 26)
p
Hemoglobin (g%) 6.16  1.98 8.42  1.09 9.33  1.99 10.41  1.25 0.006
RBCs ( 106/mL) 3.19  0.89 3.95  0.64 4.01  0.39 4.92  0.68 0.016
Hematocrit (%) 20.86  2.63 27.83  3.46 29.82  2.97 31.28  3.74 0.003
Data are presented as mean  standard deviation.
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19. These populations include people with hemolytic dis-
orders that cause an increased rate of erythrocyte
destruction.13 Some epidemiological studies of several
countries showed that the prevalence of PB-19 infections
varied among countries and populations.6,14
Miron et al,15 Zimmerman et al,16 and Salvov et al17
studied acute PB-19 in hospitalized children and demon-
strated that both serum PB-19 IgM and detection of PB-19
DNA by PCR are informative and that the evaluation of
both is necessary to achieve a high level of diagnostic ac-
curacy. In other studies, it was suggested that chronic PB-
19 infection was demonstrated by the presence of PB-19
DNA and anti-PB-19 IgG in patients’ sera in the absence of
anti-PB-19 IgM.12,18
Our study demonstrated that 30% of the studied patients
with sickle cell disease have acute PB-19 infection and 24%
of them have chronic infection, while 20% of them have an
old infection. Almost similar rates were recorded by studies
done in USA and Guinea on patients with sickle cell ane-
mia.1,3 Higher seroprevalence of anti-PB-19 IgG in patients
with hematological disorders including thalassemia and
sickle cell disease were reported in Taiwan, Sweden, and
Nigeria.12,19,20 In agreement with the current data, the
prevalence of IgG antibodies in patients with several types
of chronic hemolytic anemia was 56% in Egypt,21 40% and
68% in Saudi Arabia,2,22 and 56.5% in Tunisia.8
The present study also revealed that PB-19 infection,
especially acute infection, is a major contributor to severe
anemia in children with sickle cell disease. Anemia was
worse in children with acute PB-19 infection than in those
with chronic infection, while anemia was mild in childrenPlease cite this article in press as: Makhlouf MM, et al., Molecular an
children with sickle cell disease, Journal of Microbiology, Im
j.jmii.2015.10.016with old PB-19 infection. This finding is reminiscent of other
researches3,17,23 that reported a serological association
between acute PB-19 infection and severe anemia. These
reports also stated that children with hemolytic disorder
would have an even larger decrease in hemoglobin levels if
they developed the PB-19 infection and they might be even
more prone to PB-19 induced severe anemia.
The strength of association between PB-19 and severe
anemia observed in the present study indicates that the
prevention of PB-19 infection is likely to result in burden of
severe anemia in children with sickle cell disease in Egypt.
Efforts to develop a safe and effective vaccine against PB-
19, which is already being investigated, should be
strengthened by the view of its possible use in the pre-
vention of severe anemia among children with chronic he-
molytic anemia.21,24
In conclusion, PB-19 infection is detected in high rates
among Egyptian children with sickle cell disease and it may
result in severe anemia. Therefore, PB-19 must be sus-
pected and screened for in such group of patients.
Screening of blood for PB-19 may be helpful in under-
standing the epidemiology of infection with this virus. The
direct detection of DNA by PCR in sera needs to be coupled
with serology for a more reliable diagnosis of PB-19 in-
fections in these children. Further studies for genotyping
and quantification of the virus will be more useful for
diagnosis and staging of infection.Conflicts of interest
The authors state that there are no conflicts of interest.d serological assessment of parvovirus B-19 infection in Egyptian
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